JP2022522776A5 - - Google Patents
Info
- Publication number
- JP2022522776A5 JP2022522776A5 JP2021551770A JP2021551770A JP2022522776A5 JP 2022522776 A5 JP2022522776 A5 JP 2022522776A5 JP 2021551770 A JP2021551770 A JP 2021551770A JP 2021551770 A JP2021551770 A JP 2021551770A JP 2022522776 A5 JP2022522776 A5 JP 2022522776A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dose
- pharmaceutical composition
- composition according
- vector genome
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962813597P | 2019-03-04 | 2019-03-04 | |
| US62/813,597 | 2019-03-04 | ||
| US201962839457P | 2019-04-26 | 2019-04-26 | |
| US62/839,457 | 2019-04-26 | ||
| PCT/US2020/020929 WO2020180951A1 (en) | 2019-03-04 | 2020-03-04 | Sequential intravitreal administration of aav gene therapy to contralateral eyes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522776A JP2022522776A (ja) | 2022-04-20 |
| JP2022522776A5 true JP2022522776A5 (enExample) | 2023-03-13 |
| JP7597380B2 JP7597380B2 (ja) | 2024-12-10 |
Family
ID=70334029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021551770A Active JP7597380B2 (ja) | 2019-03-04 | 2020-03-04 | 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200297869A1 (enExample) |
| EP (1) | EP3934698A1 (enExample) |
| JP (1) | JP7597380B2 (enExample) |
| KR (1) | KR20210135267A (enExample) |
| AU (1) | AU2020231505A1 (enExample) |
| WO (1) | WO2020180951A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CN114250227B (zh) * | 2020-09-25 | 2026-04-03 | 北京安龙生物医药有限公司 | 用于高水平表达外源基因的表达载体 |
| AU2021378270A1 (en) * | 2020-11-10 | 2023-06-15 | Avirmax Biopharma Inc. | Engineered viral capsids and methods of use |
| AU2022253065A1 (en) * | 2021-04-09 | 2023-09-28 | Avirmax Biopharma Inc. | Compositions and methods for ocular transgene expression |
| CN117222400A (zh) * | 2021-04-27 | 2023-12-12 | 阿德夫拉姆生物技术股份有限公司 | 使用编码阿柏西普的aav2变体治疗眼部疾病的方法 |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| KR20240152351A (ko) * | 2022-02-17 | 2024-10-21 | 스카이라인 테라퓨틱스 리미티드 | 변형된 aav 캡시드 폴리펩티드를 갖는 재조합 아데노-연관 바이러스 |
| CA3252767A1 (en) | 2022-06-07 | 2023-12-14 | Adverum Biotechnologies, Inc. | VARIANTS OF MELANOPSINE FOR VISION RESTORATION |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024168252A2 (en) * | 2023-02-10 | 2024-08-15 | Yale University | Use of inhibitors of vegf-c signaling for inhibiting immune responses and increasing gene therapy efficacy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053703A2 (en) * | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9725485B2 (en) * | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| LT3137497T (lt) * | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| FI3265178T3 (fi) * | 2015-03-02 | 2026-08-03 | Adverum Biotechnologies Inc | Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin |
| ES2908467T3 (es) * | 2016-04-29 | 2022-04-29 | Adverum Biotechnologies Inc | Evasión de anticuerpos neutralizantes por un virus adenoasociado recombinante |
| CN117531025A (zh) * | 2016-06-16 | 2024-02-09 | 阿德夫拉姆生物技术股份有限公司 | 使用aav2变体和阿柏西普治疗amd |
| AU2017345470B2 (en) * | 2016-10-19 | 2023-08-03 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| JP2020510424A (ja) * | 2017-02-28 | 2020-04-09 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | 改変ａａｖカプシドおよびその使用 |
| KR102616820B1 (ko) | 2017-03-17 | 2023-12-21 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 향상된 유전자 발현을 위한 조성물 및 방법 |
-
2020
- 2020-03-04 WO PCT/US2020/020929 patent/WO2020180951A1/en not_active Ceased
- 2020-03-04 KR KR1020217031241A patent/KR20210135267A/ko not_active Ceased
- 2020-03-04 AU AU2020231505A patent/AU2020231505A1/en active Pending
- 2020-03-04 JP JP2021551770A patent/JP7597380B2/ja active Active
- 2020-03-04 EP EP20720552.7A patent/EP3934698A1/en not_active Withdrawn
- 2020-03-04 US US16/808,932 patent/US20200297869A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2021503914A5 (enExample) | ||
| CN113766934B (zh) | 用于玻璃体内递送的变体aav衣壳 | |
| JP2022529775A5 (enExample) | ||
| JP7597380B2 (ja) | 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与 | |
| US20190142975A1 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| CN113121652A (zh) | 视网膜和肌肉高亲和性腺相关病毒衣壳蛋白及相关应用 | |
| CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
| JP7842082B2 (ja) | 眼疾患を処置するための組成物および方法 | |
| JP2022523679A (ja) | 体液性免疫を回避する組成物および方法 | |
| RU2018143411A (ru) | Лечение комплемент-опосредуемых расстройств | |
| US20250340900A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| JP2025501286A (ja) | 修飾されたａａｖカプシドタンパク質及びその使用 | |
| JP2021511030A5 (enExample) | ||
| CN110423281A (zh) | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 | |
| JP2023545229A5 (enExample) | ||
| WO2018057916A1 (en) | Novel humanized anti-ebola antibodies useful in preventing ebola infections | |
| CN114276419B (zh) | 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用 | |
| CN113121655A (zh) | 眼部和肌肉特异靶向型腺相关病毒载体及其应用 | |
| JP2025506681A5 (enExample) | ||
| WO2022222869A1 (zh) | 重组腺相关病毒及其应用 | |
| Kim et al. | AAV-based gene therapies for neovascular AMD | |
| WO2025034741A1 (en) | Compositions and methods for expressing therapeutics | |
| TW202508610A (zh) | 醫藥組成物及其用途 | |
| CN117085148A (zh) | 一种治疗眼病或病症的方法 |